Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells

Journal of Experimental Medicine

Volumn 208, Issue 10, 2011, Pages 2005-2016

  Fuertes, Mercedes B ^a   Kacha, Aalok K ^a   Kline, Justin ^a   Woo, Seng Ryong ^a   Kranz, David M ^b   Murphy, Kenneth M ^c   Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; B7 ANTIGEN; BETA INTERFERON; BETA INTERFERON RECEPTOR; CD40 ANTIGEN; CD86 ANTIGEN; CD8ALPHA ANTIGEN; GLYCOPROTEIN P 15095; INTERFERON; STAT1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CANCER CONTROL; CANCER TISSUE; CANCER TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; DENDRITIC CELL; GENETIC TRANSCRIPTION; HEMATOPOIETIC CELL; HOST; HUMAN; HUMAN CELL; INNATE IMMUNITY; INTERFERON PRODUCTION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR IMMUNITY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOCYTE SUBSETS; MELANOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

EID: 80355136945     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20101159     Document Type: Article

References (56)

1. Anderson, M.J., K. Shafer-Weaver, N.M. Greenberg, and A.A. Hurwitz. 2007. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J. Immunol. 178:1268-1276.
2. Anichini, A., A. Molla, R. Mortarini, G. Tragni, I. Bersani, M. Di Nicola, A.M. Gianni, S. Pilotti, R. Dunbar, V. Cerundolo, and G. Parmiani. 1999. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J. Exp. Med. 190:651-667. http://dx.doi.org/10.1084/jem.190.5.651
3. Apetoh, L., F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz, A. Criollo, G. Mignot, M.C. Maiuri, E. Ullrich, P. Saulnier, et al. 2007. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13:1050-1059. http://dx.doi.org/10.1038/nm1622
4. Basu, S., R.J. Binder, R. Suto, K.M. Anderson, and P.K. Srivastava. 2000. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol. 12:1539-1546. http://dx.doi.org/10.1093/intimm/12.11.1539
5. Belz, G.T., C.M. Smith, D. Eichner, K. Shortman, G. Karupiah, F.R. Carbone, and W.R. Heath. 2004. Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses. J. Immunol. 172:1996-2000.
6. Berhanu, A., J. Huang, S.M. Alber, S.C. Watkins, and W.J. Storkus. 2006. Combinational FLt3 ligand and granulocyte macrophage colonystimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy. Cancer Res. 66:4895-4903. http://dx.doi.org/10.1158/0008-5472.CAN-05-2384
7. Boon, T., and L.J. Old. 1997. Cancer Tumor antigens. Curr. Opin. Immunol. 9:681-683. http://dx.doi.org/10.1016/S0952-7915(97)80049-0
8. Dorner, B.G., M.B. Dorner, X. Zhou, C. Opitz, A. Mora, S. Güttler, A. Hutloff, H.W. Mages, K. Ranke, M. Schaefer, et al. 2009. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells. Immunity. 31:823-833. http://dx.doi.org/10.1016/j.immuni.2009.08.027
9. Dunn, G.P., A.T. Bruce, K.C. Sheehan, V. Shankaran, R. Uppaluri, J.D. Bui, M.S. Diamond, C.M. Koebel, C. Arthur, J.M. White, and R.D. Schreiber. 2005. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 6:722-729. http://dx.doi.org/10.1038/ni1213
10. Dunn, G.P., C.M. Koebel, and R.D. Schreiber. 2006. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6:836-848. http://dx.doi.org/10.1038/nri1961
11. Fallarino, F., C. Uyttenhove, T. Boon, and T.F. Gajewski. 1996. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol. 156:1095-1100.
12. Fortunato, G., G. Calcagno, V. Bresciamorra, E. Salvatore, A. Filla, S. Capone, R. Liguori, S. Borelli, I. Gentile, F. Borrelli, et al. 2008. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J. Interferon Cytokine Res. 28:141-152. http://dx.doi.org/10.1089/jir.2007.0049
13. Gajewski, T.F., J.C. Renauld, A. Van Pel, and T. Boon. 1995. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J. Immunol. 154: 5637-5648.
14. Ghiringhelli, F., L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma, C. Ortiz, K. Vermaelen, T. Panaretakis, G. Mignot, E. Ullrich, et al. 2009. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1betadependent adaptive immunity against tumors. Nat. Med. 15:1170-1178. http://dx.doi.org/10.1038/nm.2028
15. Gresser, I., F. Belardelli, C. Maury, M.T. Maunoury, and M.G. Tovey. 1983. Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors. J. Exp. Med. 158:2095-2107. http://dx.doi.org/10.1084/jem.158.6.2095
16. Haag, F., S. Adriouch, A. Braß, C. Jung, S. Möller, F. Scheuplein, P. Bannas, M. Seman, and F. Koch-Nolte. 2007. Extracellular NAD and ATP: Partners in immune cell modulation. Purinergic Signal. 3:71-81. http://dx.doi.org/10.1007/s11302-006-9038-7
17. Harlin, H., T.V. Kuna, A.C. Peterson, Y. Meng, and T.F. Gajewski. 2006. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol. Immunother. 55:1185-1197. http://dx.doi.org/10.1007/s00262-005-0118-2
18. Harlin, H., Y. Meng, A.C. Peterson, Y. Zha, M. Tretiakova, C. Slingluff, M. McKee, and T.F. Gajewski. 2009. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69:3077-3085. http://dx.doi.org/10.1158/0008-5472.CAN-08-2281
19. Hildner, K., B.T. Edelson, W.E. Purtha, M. Diamond, H. Matsushita, M. Kohyama, B. Calderon, B.U. Schraml, E.R. Unanue, M.S. Diamond, et al. 2008. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 322:1097-1100. http://dx.doi.org/10.1126/science.1164206
20. Holler, P.D., L.K. Chlewicki, and D.M. Kranz. 2003. TCRs with high affinity for foreign pMHC show self-reactivity. Nat. Immunol. 4:55-62. http://dx.doi.org/10.1038/ni863
21. Huang, A.Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:961-965. http://dx.doi.org/10.1126/science.7513904
22. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R.M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693-1702. http://dx.doi.org/10.1084/jem.176.6.1693
23. Ishii, K.J., K. Suzuki, C. Coban, F. Takeshita, Y. Itoh, H. Matoba, L.D. Kohn, and D.M. Klinman. 2001. Genomic DNA released by dying cells induces the maturation of APCs. J. Immunol. 167:2602-2607.
24. Ishikawa, H., Z. Ma, and G.N. Barber. 2009. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 461:788-792. http://dx.doi.org/10.1038/nature08476
25. Jung, S., D. Unutmaz, P. Wong, G. Sano, K. De los Santos, T. Sparwasser, S. Wu, S. Vuthoori, K. Ko, F. Zavala, et al. 2002. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity. 17:211-220. http://dx.doi.org/10.1016/S1074-7613(02)00365-5
26. Kacha, A.K., F. Fallarino, M.A. Markiewicz, and T.F. Gajewski. 2000. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J. Immunol. 165:6024-6028.
27. Kline, J., I.E. Brown, Y.Y. Zha, C. Blank, J. Strickler, H. Wouters, L. Zhang, and T.F. Gajewski. 2008. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin. Cancer Res. 14:3156-3167. http://dx.doi.org/10.1158/1078-0432.CCR-07-4696
28. Kono, H., and K.L. Rock. 2008. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8:279-289. http://dx.doi.org/10.1038/nri2215
29. Kranz, D.M., S. Tonegawa, and H.N. Eisen. 1984. Attachment of an antireceptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA. 81:7922- 7926. http://dx.doi.org/10.1073/pnas.81.24.7922
30. Krug, A., A.R. French, W. Barchet, J.A. Fischer, A. Dzionek, J.T. Pingel, M.M. Orihuela, S. Akira, W.M. Yokoyama, and M. Colonna. 2004. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity. 21:107-119. http://dx.doi.org/10.1016/j.immuni.2004.06.007
31. Le Bon, A., N. Etchart, C. Rossmann, M. Ashton, S. Hou, D. Gewert, P. Borrow, and D.F. Tough. 2003. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4:1009-1015. http://dx.doi.org/10.1038/ni978
32. Luber, C.A., J. Cox, H. Lauterbach, B. Fancke, M. Selbach, J. Tschopp, S. Akira, M. Wiegand, H. Hochrein, M. O'Keeffe, and M. Mann. 2010. Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity. 32:279-289. http://dx.doi.org/10.1016/j.immuni.2010.01.013
33. Mortarini, R., A. Piris, A. Maurichi, A. Molla, I. Bersani, A. Bono, C. Bartoli, M. Santinami, C. Lombardo, F. Ravagnani, et al. 2003. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res. 63:2535-2545.
34. Motzer, R.J., J. Bacik, B.A. Murphy, P. Russo, and M. Mazumdar. 2002. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20:289-296. http://dx.doi.org/10.1200/JCO.20.1.289
35. Muldoon, J., A. Uriel, S. Khoo, W.E. Ollier, and A.H. Hajeer. 2001. Novel IFN-alpha receptor promoter polymorphisms. Genes Immun. 2:159- 160. http://dx.doi.org/10.1038/sj.gene.6363757
36. Neidhart, J.A., M.M. Gagen, D. Young, R. Tuttle, T.J. Melink, A. Ziccarrelli, and D. Kisner. 1984. Interferon-alpha therapy of renal cancer. Cancer Res. 44:4140-4143.
37. Peterson, A.C., H. Harlin, and T.F. Gajewski. 2003. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J. Clin. Oncol. 21:2342-2348. http://dx.doi.org/10.1200/JCO.2003.12.144
38. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190:705-715. http://dx.doi.org/10.1084/jem.190.5.705
39. Preynat-Seauve, O., P. Schuler, E. Contassot, F. Beermann, B. Huard, and L.E. French. 2006. Tumor-infiltrating dendritic cells are potent antigenpresenting cells able to activate T cells and mediate tumor rejection. J. Immunol. 176:61-67.
40. Rabinovich, G.A., D. Gabrilovich, and E.M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25:267-296. http://dx.doi.org/10.1146/annurev.immunol.25.022106.141609
41. Randolph, G.J., J. Ochando, and S. Partida-Sánchez. 2008. Migration of dendritic cell subsets and their precursors. Annu. Rev. Immunol. 26:293-316. http://dx.doi.org/10.1146/annurev.immunol.26.021607.090254
42. Scaffidi, P., T. Misteli, and M.E. Bianchi. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191- 195. http://dx.doi.org/10.1038/nature00858
43. Sha, W.C., C.A. Nelson, R.D. Newberry, D.M. Kranz, J.H. Russell, and D.Y. Loh. 1988. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature. 335:271-274. http://dx.doi.org/10.1038/335271a0
44. Shi, Y., J.E. Evans, and K.L. Rock. 2003. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 425:516- 521. http://dx.doi.org/10.1038/nature01991
45. Speiser, D.E., D. Liénard, M.J. Pittet, P. Batard, D. Rimoldi, P. Guillaume, J.C. Cerottini, and P. Romero. 2002. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur. J. Immunol. 32:731-741.
46. Stark, G.R., I.M. Kerr, B.R. Williams, R.H. Silverman, and R.D. Schreiber. 1998. How cells respond to interferons. Annu. Rev. Biochem. 67:227- 264. http://dx.doi.org/10.1146/annurev.biochem.67.1.227
47. Stetson, D.B., and R. Medzhitov. 2006a. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity. 24: 93-103. http://dx.doi.org/10.1016/j.immuni.2005.12.003
48. Stetson, D.B., and R. Medzhitov. 2006b. Type I interferons in host defense. Immunity. 25:373-381. http://dx.doi.org/10.1016/j.immuni.2006.08.007
49. Takaoka, A., Z. Wang, M.K. Choi, H. Yanai, H. Negishi, T. Ban, Y. Lu, M. Miyagishi, T. Kodama, K. Honda, et al. 2007. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature. 448:501-505. http://dx.doi.org/10.1038/nature06013
50. Tan, E.M., and J. Zhang. 2008. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol. Rev. 222:328-340. http://dx.doi.org/10.1111/j.1600-065X.2008.00611.x
51. Udaka, K., K.H. Wiesmüller, S. Kienle, G. Jung, and P. Walden. 1996. Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J. Immunol. 157:670-678.
52. Valmori, D., V. Dutoit, V. Rubio-Godoy, C. Chambaz, D. Liénard, P. Guillaume, P. Romero, J.C. Cerottini, and D. Rimoldi. 2001. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res. 61:509-512.
53. Vesely, M.D., M.H. Kershaw, R.D. Schreiber, and M.J. Smyth. 2011. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29:235- 271. http://dx.doi.org/10.1146/annurev-immunol-031210-101324
54. Wang, X., J. Yu, A. Sreekumar, S. Varambally, R. Shen, D. Giacherio, R. Mehra, J.E. Montie, K.J. Pienta, M.G. Sanda, et al. 2005. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 353:1224-1235. http://dx.doi.org/10.1056/NEJMoa051931
55. Zhang, B., N.A. Bowerman, J.K. Salama, H. Schmidt, M.T. Spiotto, A. Schietinger, P. Yu, Y.X. Fu, R.R. Weichselbaum, D.A. Rowley, et al. 2007. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204:49-55. http://dx.doi.org/10.1084/jem.20062056
56. Zhang, B., Y. Zhang, N.A. Bowerman, A. Schietinger, Y.X. Fu, D.M. Kranz, D.A. Rowley, and H. Schreiber. 2008. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res. 68:1563-1571. http://dx.doi.org/10.1158/0008-5472.CAN-07-5324